Primary headache disorders, but particularly migraine, are hugely prevalent in the TMD population, and considered to be comorbid conditions. This presentation will discuss the significance of this comorbidity, outlining its bidirectional clinical relationship, how each condition can exacerbate overall clinical outcomes and affect management strategies. It will also highlight the need for a better understanding of its underlying mechanisms to help support evidence based novel treatments. In this light, the latest preclinical research will be discussed that has shown how the development of more translational animal models has helped us to begin to dissect the neurophysiological mechanisms behind this comorbidity and its symptomatic phenotype. With the development of these novel preclinical approaches there has been fresh opportunity to identify some unique underlying molecular mechanisms involved in TMD/migraine comorbidity that will be reviewed. Finally, based on these preclinical findings, several potentially novel avenues for treatment will be highlighted that may offer new hope to this complex patient population.
SECRETARÍA TÉCNICA